|
Costa Rica HPV Vaccine Trial (IR Travel)
|
Cures Moonshot18I2
|
$89,783
|
N/A
|
N/A
|
|
Costa Rica HPV Vaccine Trial (IR)
|
Cures Moonshot18I3
|
$1,078,107
|
N/A
|
N/A
|
|
IDDA - Partner - CDC
|
NIH-18-013
|
$678,899
|
N/A
|
N/A
|
|
IDDA - Partner - HRSA
|
NIH-18-017
|
$700,000
|
N/A
|
N/A
|
|
IDDA - Partner - CDC
|
NIH-18-018
|
$74,250
|
N/A
|
N/A
|
|
IDDA - Partner - CDC
|
NIH-18-025
|
$127,224
|
N/A
|
N/A
|
|
IGF::OT::IGF Hosting, Maintenance and Professional services for Rave and Medidata Rave Integrated Software
|
261201800033I
|
$5,576,825
|
-, -
|
-
|
|
The purpose of this procurement is to provide strategic planning and support service for the NCI CBITT
|
261201800285P
|
$24,876
|
-, -
|
-
|
|
Electronic Capture of Cancer Claims Data for SEER Program
|
261201800649P
|
$245,000
|
-, -
|
-
|
|
RIESSEARCH, LLC:1164941 [18-046091]
|
261201800744P
|
$22,800
|
-, -
|
-
|
|
IGF::OT::IGF CORE SUPPORT ACTIVITIES: SCIENTIFIC WRITING, TECHNICAL AND LOGISTICAL SUPPORT SERVICES
|
261201700004I
|
$1,200,000
|
BIZZELL, ANTON
|
-
|
|
BUSINESS ANALYST SERVICES TO ACHIEVE A BETTER UNDERSTANDING OF THE BUSINESS PROCESSES OF THE THE FEDERALLY FUNDED RESEARCH AND DEVELOPMENT CENTER (FFRDC) CONTRACTORS BUSINESS SYSTEMS.
|
261201800005A
|
$315,922
|
DURAND, HANK
|
-
|
|
CBCSLC CONTRACT FOR THE NCI CHEMICAL BIOLOGY CONSORTIUM, TO# 1
|
261201500010I
|
$275,323
|
JOHNSON, CHARLES
|
-
|
|
IGF::OT::IGF OPERATION & SUPPORT OF THE CTEP PROTOCOL AND INFORMATION OFFICE (PIO)
|
261201600003C
|
$1,232,875
|
KIERNAN, SHERYL
|
-
|
|
IGF::OT::IGF OTHER FUNCTIONS - IRB MANAGER SOFTWARE. OPTION YEAR TWO
|
261201600195P
|
$168,000
|
LEVERICH, WALDEN
|
-
|
|
IGF::OT::IGF CABEZON GROUP INC:1133841 [16-038312]
|
261201200005I
|
$50,125
|
RATEL, RACHEL
|
-
|
|
TOPIC 373 - PHASE I SBIR - ABZYME THERAPEUTICS, LLC - Moonshot
|
261201800031C
|
$299,999
|
N/A
|
ABZYME THERAPEUTICS, LLC
|
|
IGF::OT::IGF OTHER FUNCTIONS. Healthcare Delivery Research Visiting Scholars Program.
|
261201800642P
|
$51,283
|
-, -
|
ACADEMYHEALTH
|
|
Integrin Regulation of Cancer Progression Through Alternative mRNA Splicing and Nonsense-Medidated Decay (NMD)
|
5R01CA129637-08
|
$375,250
|
DIPERSIO, C MICHAEL
|
ALBANY MEDICAL COLLEGE
|
|
Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer
|
5R01CA128943-10
|
$396,625
|
DI CRISTOFANO, ANTONIO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
IGF::OT::IGF IGF::OF::IGF- PHASE III TRIAL OF CARBON ION THERAPY
|
261201500022C
|
$462,158
|
GUHA, CHANDAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
IGF::OT::IGF MANUFACTURE OF BULK CHEMICALS AND BULK PHARMACEUTICAL INGREDIENTS FOR PRECLINICAL AND CLINICAL STUDIES
|
261201700020C
|
$671,205
|
DENYSENKO, SERGIY
|
ALCHEM LABORATORIES CORPORATION
|
|
IGF::OT::IGF NON-GMP SYNTHESIS OF COMPOUNDS FOR DRUG DEVELOPMENT
|
261201600066C
|
$549,643
|
RUDCHENKO, VLADIMIR
|
ALCHEM LABORATORIES CORPORATION
|
|
IGF::OT::IGF SYNTHESIS OF 30 GRAMS OF THE TARGET COMPOUND, TASK ORDER PERIOD OF PERFORMANCE: 2/28/2018-4/27/2018.
|
261201700007I
|
$96,648
|
ZHANG, MIANJI
|
ALCHEM LABORATORIES CORPORATION
|
|
IGF::OT::IGF SITE LICENSE TO AJCC CANCER STAGING MANUAL, 8TH EDITION, IN SUPPORT OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS), NATIONAL INSTITUTES OF HEALTH (NIH), NATIONAL CANCER INSTITUTE
|
261201800122P
|
$125,000
|
MADERA, MARTIN
|
AMERICAN COLLEGE OF SURGEONS
|
|
IGF::OT::IGF Protocol Information Office (PIO) Support Services
|
261201800045C
|
$630,000
|
-, -
|
ARSERVICES, LTD
|
|
Task Order HHSN26100004 issued for: Task 1 - Operational Support and Configuration Changes and Task ePath Installation.
|
261201500033I
|
$810,970
|
-, -
|
ARTIFICIAL INTELLIGENCE IN MEDICINE, INC
|
|
Dietary Combination For Prevention of Metastatic Renal Cell Carcinoma
|
5R01CA176691-05
|
$341,059
|
LOKESHWAR, VINATA
|
AUGUSTA UNIVERSITY
|
|
Role of heat shock factors (Hsfs) in tumorigenesis
|
5R01CA132640-17
|
$270,000
|
MIVECHI, NAHID
|
AUGUSTA UNIVERSITY
|
|
DEVELOPMENT AND VALIDATION OF NON- MOUSE REAGENTS TO ENABLE PRECLINICAL DEVELOPMENT OF NOVEL THERAPEUTICS - Moonshot
|
261201800041C
|
$299,854
|
N/A
|
AVANTGEN INC
|
|
DACH1/Eya Cell fate determination factor and mammary tumorigenesis
|
5R01CA132115-09
|
$428,056
|
PESTELL, RICHARD
|
BARUCH S. BLUMBERG INSTITUTE
|
|
TOPIC 372 - PHASE I SBIR - BASE PAIR,LLC - Moonshot
|
261201800040C
|
$300,000
|
N/A
|
BASE PAIR BIOTECHNOLOGIES, INC.
|
|
Preclinical Analyses of NAD Kinase as a Redox Vulnerability for the Treatment of Pancreatic Cancer
|
5R01CA211176-02
|
$362,569
|
ELSEA, SARAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
Computational and Experimental Modeling of Alternative Polyadenylation
|
5R01CA193466-03
|
$361,128
|
LI, WEI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Ruxolitinib for Preventing Breast Cancer in Women on Neuroleptics
|
5R01CA205594-02
|
$362,569
|
LI, YI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Novel therapeutics for targeting checkpoint dysfunction in cancer
|
5R01CA203824-02
|
$362,569
|
LIN, WEEI-CHIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
NCOA6, A Novel Tumor Suppressor of Endometrial Cancer
|
5R01CA193455-03
|
$86,504
|
XU, JIANMING
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Effects of High Fructose Corn Syrup on Intestinal Tumorigenesis
|
1K22CA216036-01
|
$179,877
|
YUN, JIHYE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Image-guided irradiation safely intensifies HSCT regimen for refractory leukemia
|
5R01CA195519-03
|
$238,425
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Biologic and Therapeutic Significance of miR-155 in AML
|
5R01CA201184-03
|
$549,553
|
MARCUCCI, GUIDO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Phase I Molecular and Clinical Pharmacodynamic Trials ET-CTN
|
5UM1CA186717-04
|
$2,015,876
|
NEWMAN, EDWARD
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Reolysin-based combination therapy in relapsed multiple myeloma
|
5R01CA194742-03
|
$574,645
|
PICHIORRI, FLAVIA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Dynamic functions of DNA2 counteract DNA replication stresses and tumorigenesis
|
5R01CA085344-19
|
$294,000
|
SHEN, BINGHUI
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Personalized vaccine for patients with AML
|
5R01CA212649-02
|
$721,179
|
AVIGAN, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Modeling KRAS genetic heterogeneity in mouse models
|
5R01CA195744-03
|
$635,205
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
MiR-199~214 cluster at the crossroads of plasticity and malignancy in breastcancer
|
5R01CA207322-02
|
$395,738
|
KARNOUB, ANTOINE
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting PML for Leukemia Therapy
|
5R01CA142874-08
|
$457,619
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Passive and active targeting of unnatural chemokine fusions for cancer immunotherapies
|
1F32CA220990-01
|
$61,174
|
FANG, TAO
|
BOSTON CHILDREN'S HOSPITAL
|
|
Regulation of the LIN28/let-7 pathway in cancer
|
5R01CA211328-02
|
$404,888
|
GREGORY, RICHARD
|
BOSTON CHILDREN'S HOSPITAL
|
|
Novel Role(s) of Nrf2 in the Growth of Post-Transplantation Cancer
|
5R01CA193675-03
|
$404,888
|
PAL, SOUMITRO
|
BOSTON CHILDREN'S HOSPITAL
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|